Collection of Blood in Studying Metabolites in Patients With Prostate Cancer

Metabolic Profiling of Peripheral Blood Mononuclear Cells (PBMCs) by LC-MS in Prostate Cancer Patients

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03485794

Enrollment

Registered

2018-04-02

Start date

2017-11-14

Completion date

2024-01-02

Last updated

2025-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Carcinoma

Brief summary

This pilot research trial utilizes the collection of blood in studying metabolites in patients with prostate cancer. Metabolites are the small molecule products of cellular metabolism that are produced naturally in all living cells. Collecting blood in order to study metabolites may help doctors monitor and treat prostate cancer more effectively.

Detailed description

PRIMARY OBJECTIVES: I. Develop blood sample collection and preparation procedures for reliable, meaningful metabolomic profiling of peripheral blood mononuclear cells (PBMCs) by liquid chromatography/quadruple-time of flight/mass spectrometry (LC/Q-TOF/MS) that can be implemented in a clinical setting. II. Optimize data analysis methods and software usage to create a metabolic profile for patients at the time of blood collection. III. Compare metabolite profiles of isolated PBMCs versus (vs.) other blood fractions (plasma, red blood cells \[RBCs\], and whole blood). IV. Identify elements of the PBMC metabolite profile that may correlate to patient disease state. OUTLINE: Patients undergo collection of blood for metabolic profiling via LC/Q-TOF/MS.

Interventions

PROCEDUREBiospecimen Collection

Undergo collection of blood

OTHERLaboratory Biomarker Analysis

Correlative studies

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* All subjects will have histologically confirmed prostate cancer * Provide written consent/authorization to participate in this study * Have no signs or symptoms of active infection * Exhibit a willingness to comply with the experimental procedures as outlined in this protocol

Design outcomes

Primary

Measure	Time frame	Description
Blood sample collection	Baseline	The blood will be used to analyze the metabolites produced by white blood cells.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026